|
|
Article: DYNOGEN ACQUIRES EXCLUSIVE RIGHTS TO PUMOSETRAG.
- Article from:
- Worldwide Biotech
- Article date:
- December 1, 2004
CopyrightCOPYRIGHT 2004 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dynogen Pharmaceuticals, Inc. Waltham, Mass., has acquired an exclusive license to the clinical-stage compound pumosetrag from Mitsubishi Pharma Corporation. Pumosetrag was previously studied by Mitsubishi in Phase II clinical trials where it demonstrated favorable safety and pharmacokinetic profiles. Dynogen will be initiating clinical studies with pumosetrag in the gastrointestinal (GI) area beginning in 2005. Financial terms of the deal were not disclosed.
In addition to issued patents and pending patent applications covering the composition of matter and its use, Dynogen's license includes exclusive rights to all pre-clinical, clinical and manufacturing data ...